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Abstract
 
Adenosine deaminase (ADA) is a purine catabolic enzyme that manages levels of the biologi-
 
cally active purines adenosine and 2
 
9
 
-deoxyadenosine in tissues and cells. ADA-deficient mice
die at 3 wk of age from severe respiratory distress. This phenotype is progressive and is linked
to perturbations in pulmonary purine metabolism. The inflammatory changes found in the
lungs of ADA-deficient mice included an accumulation of activated alveolar macrophages and
eosinophils. These changes were accompanied by a pronounced enlargement of alveolar spaces
and increases in mucus production in the bronchial airways. The alveolar enlargement was
found to be due in part to abnormal alveogenesis. Lowering adenosine and 2
 
9
 
-deoxyadenosine
levels using ADA enzyme therapy decreased the pulmonary eosinophilia and resolved many of
the lung histopathologies. In addition, genetically restoring ADA to the forestomach of other-
wise ADA-deficient mice prevented adenine metabolic disturbances as well as lung inflamma-
tion and damage. These data suggest that disturbances in purinergic signaling mediate the lung
inflammation and damage seen in ADA-deficient mice.
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Introduction
 
Adenosine deaminase (ADA)
 
1
 
 is an essential enzyme of pu-
rine catabolism that is responsible for the hydrolytic deami-
nation of adenosine and 2
 
9
 
-deoxyadenosine to inosine and
2
 
9
 
-deoxyinosine (1). These biochemical pathways are es-
sential for maintaining homeostasis, as both ADA substrates
have substantial signaling properties. Adenosine engages G
protein–coupled receptors on the surface of target cells to
evoke a variety of cellular responses (2), whereas 2
 
9
 
-deoxy-
adenosine is cytotoxic via mechanisms that interfere with
cellular growth and differentiation (3, 4) or the promotion
of apoptosis (5, 6). ADA deficiency in humans results in
marked accumulations of both of these signaling molecules,
and these accumulations are associated with a variety of cel-
lular phenotypes. The most thoroughly studied phenotype
has been the effect of this enzyme deficiency on the im-
mune system. ADA deficiency results in a combined im-
munodeficiency characterized by a severe T, B, and NK
cell lymphopenia (7, 8). Most studies identify the accumu-
lation of 2
 
9
 
-deoxyadenosine as the metabolic basis for this
lymphopenia (3, 9), although evidence exists to suggest that
engagement of adenosine receptors may be involved (10,
11). Additional phenotypes associated with ADA defi-
ciency are not as well characterized and include bony and
renal abnormalities (12), hepatocellular damage (13), neu-
rological disorders (14), and pulmonary insufficiency (7).
The metabolic basis for these phenotypes and the mecha-
nisms involved are unknown, in part due to the lack of ad-
equate models with which to study the effects of ADA de-
ficiency on these systems.
 
Address correspondence to Michael R. Blackburn, University of Texas
 
Health Science Center at Houston Medical School, Department of
Biochemistry and Molecular Biology, 6431 Fannin St., Houston, TX
 
77030. Phone: 713-500-6087; Fax: 713-500-0652; E-mail: michael.r.
 
blackburn@uth.tmc.edu
 
1
 
Abbreviations used in this paper:
 
 ADA, adenosine deaminase; BALF,
bronchial alveolar lavage fluid; H&E, hematoxylin and eosin; mMBP-1,
murine eosinophil granule major basic protein 1; PAS, periodic acid-
Schiff; PEG, polyethylene glycol. 
160
 
Lung Inflammation and Damage in ADA-deficient Mice
 
We have recently used a two-stage genetic engineering
strategy to generate ADA-deficient mice (15). The initial
knockout of the murine 
 
Ada
 
 gene resulted in a prenatal le-
thality that prevented the analysis of postnatal consequences
of ADA deficiency (16, 17). This prenatal lethality was
overcome with an ADA minigene under the control of a
trophoblast-specific promoter to restore ADA specifically
to the placenta of otherwise ADA-deficient fetuses (15,
18). This was sufficient to rescue ADA-deficient fetuses
and resulted in postnatal ADA-deficient mice amenable to
the analysis of the phenotypic and metabolic consequences
of ADA deficiency. ADA-deficient mice developed a com-
bined immunodeficiency that was linked with profound
disturbances in purine metabolism (15, 19).
In addition to immunodeficiency, ADA-deficient mice
developed other phenotypes noted in ADA-deficient hu-
mans (12), including bony and renal abnormalities and pul-
monary insufficiency (15). The most severe of these phe-
notypes was the pulmonary insufficiency. ADA-deficient
mice began to show signs of respiratory distress as early as
postpartum day 12. This distress increased in severity, and
the mice died between postpartum days 19 and 25. Initial
examination of this phenotype revealed severe lung inflam-
mation in association with severe purine metabolic distur-
bances including the accumulation of adenosine and to a
lesser extent 2
 
9
 
-deoxyadenosine (15).
Purinergic signaling has been implicated to play a role in
lung inflammation. Most notable are the well-recognized
effects of adenosine in asthma (20). Clinical evidence link-
ing adenosine to this disease state includes the detection of
elevated adenosine levels in bronchial alveolar lavage fluid
(BALF) collected from asthmatics (21); the observation that
inhaled adenosine elicits bronchoconstriction in individuals
suffering from asthma (22); the expression of adenosine re-
ceptors is altered in patients with airway inflammation (23);
and theophylline, an adenosine receptor antagonist, has a
well-recognized therapeutic benefit in this disease (24). In
addition, there are many in vitro studies that implicate aden-
osine as a modulator of inflammatory processes that are
central to asthma. These include adenosine’s ability to en-
hance (25) or directly evoke (26) mediator release from
mast cells, and to influence eosinophil function (27–29).
Adenosine signaling has also been implicated in regulating
the function of other inflammatory cells such as macro-
phages (30–32) and neutrophils (33, 34). Despite these lines of
evidence, a causative link between adenosine signaling and
lung inflammation, as well as the cell types and mechanisms
involved, are unclear. In the current study, we character-
ized the lung inflammation and damage occurring in ADA-
deficient mice. Moreover, we used ADA enzyme therapy
to demonstrate a relationship between adenosine and 2
 
9
 
-
deoxyadenosine levels and the inflammation that results in
ADA-deficient animals. The ADA-deficient mice described
exhibited many features of lung disease, including defects in
alveogenesis, activation of alveolar macrophages, lung eosin-
ophilia, and mucus hypersecretion. These pulmonary fea-
tures were closely associated with disturbances in the con-
centrations of ADA substrates, suggesting that perturbations
 
in signaling pathways accessed by these substrates are in-
volved. This model will provide a unique approach to ex-
amining the specific roles of adenosine signaling in vivo.
 
Materials and Methods
 
Transgenic Mice.
 
ADA-deficient mice were generated and
genotyped as described previously (15, 16). All mice used in these
studies were on a mixed background of 129/Sv and FVB/N
strains (18). Control mice were either wild-type animals or mice
heterozygous for the null 
 
Ada
 
 allele (15). Animal care was in ac-
cordance with institutional and National Institutes of Health
guidelines. All mice were housed in cages equipped with mi-
croisolator lids and maintained under strict containment proto-
cols. No evidence of bacterial, parasitic, or fungal infection was
found. In addition, serologies on cage littermates were negative
for 12 of the most common murine viruses.
 
Histological Analysis and Immunofluorescence.
 
Aged-matched
control and experimental animals were killed, and the lungs were
infused with 0.1–0.5 ml of fixative (4% paraformaldehyde in
PBS), depending on age, before fixation overnight at 4
 
8
 
C. Fixed
lung samples were rinsed in PBS, dehydrated, and embedded in
paraffin. Sections (5 
 
m
 
m) were collected on microscope slides and
stained with hematoxylin and eosin (H&E; Shandon-Lipshaw) or
periodic acid-Schiff (PAS; EM Science), according to manufac-
turer’s instructions. Immunofluorescence of lungs for the expres-
sion of murine eosinophil granule major basic protein 1 (mMBP-1)
was performed according to established procedures (35). Sections
were reacted with antiserum from a rabbit immunized with puri-
fied mMBP-1, followed by detection using FITC-conjugated
anti–rabbit IgG.
 
Quantification of Lung Histopathology.
 
The size of alveolar air-
ways was determined by measuring mean chord lengths (36) on
H&E-stained lungs. Representative images were digitized, and a
grid consisting of 53 black lines at 10.5-
 
m
 
m intervals was overlaid
on the image. This line grid was subtracted from the lung images
using Image-Pro
 
®
 
 Plus (Media Cybernetics) image analysis soft-
ware, and the resultant lines were measured and averaged to give
the mean chord length of the alveolar airways. The final mean
chord lengths represent averages from 12 nonoverlapping images
of each lung specimen and are given in micrometers.
The extent of mucus production in bronchial airways was de-
termined by quantitating the amount of PAS-stained material in
the bronchial airways using Image-Pro
 
®
 
 Plus analysis software.
PAS-stained material was identified on digitized images, and the
pixel intensities of each color channel (red, blue, and green) were
averaged. This was repeated for each image, and the values were
averaged and used to determine the area (
 
M
 
) and intensity (
 
I
 
) of
PAS-stained material in bronchial airways. In addition, the area
(
 
A
 
) of the total epithelium (including PAS-stained material) was
determined. The mucus index was determined using the follow-
ing equation: 
 
M
 
 
 
3
 
 
 
I
 
/
 
A
 
. Final indices were results of an average
of eight images per lung encompassing large and small bronchial
airways.
 
Peripheral Blood Cell Counts.
 
Mice were anesthetized, and a
heparinized syringe was used to collect 200–500 
 
m
 
l of blood from
the subaxilary artery. Samples were immediately analyzed for
complete blood cell counts using an H1 Analyzer (Technicon In-
struments).
 
Bronchial Alveolar Lavages.
 
Mice were anesthetized with aver-
tin, and a blunted 21-gauge needle was secured into the trachea.
Lungs were lavaged five times with 0.25 ml PBS, and 0.95–1 ml
of pooled lavage fluid was recovered. Samples were centrifuged at 
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2,500 rpm for 5 min to recover cells, and supernatant from these
spins was collected and stored at 
 
2
 
70
 
8
 
C for the analysis of cyto-
kines. BALF cells were resuspended in 200 
 
m
 
l PBS; total cell counts
were determined from an aliquot counted using a hemocytome-
ter, and another aliquot cytospun onto microscope slides was
stained with Diff-Quik (Dade) for cellular differentials. 400 cells
per sample were identified and counted under oil immersion.
 
ELISA Assays.
 
IFN-
 
g
 
, IL-4, and IL-5 levels in BALF were
determined using specific murine OptEIA™ ELISA kits from BD
PharMingen. For the analysis of IgE levels, blood was collected
from the heart of anesthetized mice and the serum was separated
by centrifugation at 3,000 rpm for 10 min at 4
 
8
 
C. A murine Op-
tiEA ELISA kit from BD PharMingen was used to quantitate to-
tal serum IgE levels.
 
ADA Enzyme Therapy and Analysis of ADA Enzyme Activity.
 
Polyethylene glycol–modified ADA (PEG-ADA), also known as
ADAGEN
 
®
 
, was obtained through collaboration with Enzon, Inc.
Control or ADA-deficient mice were anesthetized and injected
intramuscularly with 10 
 
m
 
l of PEG-ADA corresponding to 
 
z
 
2.5 U
of ADA enzymatic activity. Injections were given either chron-
ically every 4 d starting at postpartum day 4, or acutely, as one in-
 
jection on postpartum day 18. Levels of ADA enzyme activity in
tissues were measured according to established procedures (15).
 
Quantification of Adenosine and 2
 
9
 
-Deoxyadenosine.
 
Mice were
anesthetized, the thoracic cavity was exposed, and the lungs were
removed and frozen rapidly in liquid nitrogen. Adenine nucleo-
sides were extracted from frozen lungs using 0.4 N perchloric
acid as described (37), and adenosine and 2
 
9
 
-deoxyadenosine
were separated and quantitated using reversed phase HPLC (37).
 
Results
 
Severe Lung Inflammation and Damage Are Found in the
Lungs of ADA-deficient Mice.
 
ADA-deficient mice begin
to show signs of respiratory distress as early as postpartum
day 12. This distress was characterized by rapid and labored
breathing that became increasingly severe. These mice be-
came cyanotic and died between postpartum days 19 and
25 (15). Lung inflammation was examined on postpartum
day 18 to assess the nature of the respiratory distress in
ADA-deficient mice (Fig. 1). An increase in inflammatory
Figure 1. Morphological and
cytological changes in the lungs
of ADA-deficient mice. (a)
H&E-stained control lung at
postpartum day 18. (b) H&E-
stained ADA-deficient lung at
postpartum day 18. Arrows indi-
cate areas of inflammation. No-
tice the pronounced enlarge-
ment of alveolar spaces (AS) and
the thickening of pulmonary
blood vessels (BV). (c) High
magnification of an H&E-
stained ADA-deficient lung
demonstrating eosinophil infil-
tration (arrows) around bronchi-
oles (B) and pulmonary blood
vessels (BV). (d) Immunolocal-
ization of eosinophils in an 18-
d-old ADA-deficient lung, using
a rabbit polyclonal antibody
raised against mMBP-1 followed
by detection with FITC immu-
nofluorescence. Notice intense
staining of inflammatory cells
with anti–MBP-1 (arrows).
mMBP-1 immunoreactivity was
also detected in alveolar mac-
rophages (AM). Cytological
analysis of cells collected from
BALF from the lung of an 18-d-
old ADA-deficient mouse show-
ing (e) eosinophils (arrows), (f)
alveolar macrophages engulfing
eosinophils (arrows), and (g)
multinucleated giant cells. Bars,
(a–d) 100 mm; (e–g) 10 mm. 
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cells was seen throughout the lungs, with a specific increase
of enlarged and foamy macrophages (Fig. 1 b). Closer ex-
amination of cells collected from BALF showed alveolar
macrophages engulfing eosinophils (Fig. 1 f). In addition,
multinucleated giant cells were prominent in the BALF
(Fig. 1 g). Histological analysis also suggested a pronounced
infiltration of eosinophils throughout the lungs (Fig. 1, b
and c, arrows). Lung sections were reacted with a poly-
clonal antibody against mMBP-1 (35) to confirm that the
cells were eosinophils. Results from these studies (Fig. 1 d)
confirm the accumulation of eosinophils in ADA-deficient
lungs. Eosinophils were found in interstitiary and lumenal
spaces throughout the lung, with high concentrations accu-
mulating around bronchioles and pulmonary blood vessels
(Fig. 1, b–d, arrows). Intense mMBP-1 immunoreactivity
was noted in alveolar macrophages surrounding focal points
of eosinophil accumulation (Fig. 1 d, yellow arrows), con-
firming the engulfment of eosinophils by activated mac-
rophages. A large increase in eosinophils was also found in
BALF (Fig. 1 e), and there was a twofold increase in circu-
lating eosinophils (Table I). Inflammation was not seen in
other tissues that were examined, including the gastrointes-
tinal tract, thymus, spleen, liver, and kidney (data not
shown). These results demonstrated that ADA-deficient
mice developed pronounced pulmonary inflammation
characterized by the accumulation of activated alveolar
macrophages and eosinophils.
Evidence of tissue damage and lung remodeling accom-
panied the inflammatory changes in ADA-deficient lungs.
Examination of the alveolar airways demonstrated a promi-
nent increase in the size of alveolar spaces as well as in-
creases in the thickness of the smooth muscle of pulmonary
blood vessels (Fig. 1 b). Hypertrophy of the bronchial epi-
thelium was common, as was a progressive increase in mu-
cus production and an accumulation of mucus and cellular
debris in the bronchial airways (Fig. 2). Collectively, these
results demonstrated that the pulmonary inflammation seen
in ADA-deficient mice was associated with histopathologi-
cal changes in the lung.
 
Developmental Defects in Alveogenesis Precede Lung Inflam-
mation in ADA-deficient Mice.
 
The severe inflammation
and damage seen on day 18 prompted us to examine the
development of this phenotype. At birth, control and
ADA-deficient lungs were histologically similar (Fig. 3, a
and b). At postpartum day 5, the overall morphology (Fig.
3, c and d) suggested that there was an increase in alveolar
airway size. Secondary septation of the alveoli occurred be-
tween postpartum days 5 and 10 in control mice (Fig. 3 e);
 
Table I.
 
Peripheral Blood Cell Counts
 
n
 
RBC
 
*
 
WBC
 
‡
 
Lymphocyte
 
§
 
Monocyte
 
§
 
Eosinophil
 
§
 
Neutrophil
 
§
 
Control 5 6.95 
 
6
 
 0.2 1,564 
 
6
 
 179 1,138 
 
6
 
 134 170 
 
6
 
 42 22 
 
6
 
 7 238 
 
6
 
 66
ADA-deficient 4 6.38 
 
6
 
 0.2 1,263 
 
6
 
 156 563 
 
6
 
 48
 
i
 
225 
 
6
 
 100 48 
 
6
 
 8
 
¶
 
385 
 
6
 
 111
ADA-deficient
 
1
 
PEG-ADA 3 6.17 
 
6
 
 0.2 1,187 
 
6
 
 396 623 
 
6
 
 107 207 
 
6
 
 162 23 
 
6
 
 12
 
**
 
303 
 
6
 
 151
Peripheral blood cell counts are from18-d-old control and ADA-deficient mice or ADA-deficient mice 72 h after a single dose of PEG-ADA on
day 18.
 
*
 
Mean red blood cells 
 
3
 
10
 
6
 
 
 
6
 
 SE.
 
‡
 
Mean white blood cells 
 
3
 
10
 
6
 
 
 
6
 
 SE.
 
§
 
Cells/ml 
 
6
 
 SE.
 
i
 
Statistically different from control (
 
P
 
 
 
# 
 
0.005) using a two sample 
 
t
 
 test assuming unequal variance.
 
¶
 
Statistically different from control (
 
P
 
 
 
# 
 
0.02) using a two sample 
 
t
 
 test assuming unequal variance.
 
**
 
Statistically different from ADA-deficient (
 
P
 
 
 
# 
 
0.05) using a two sample t test assuming unequal variance.
Figure 2. Mucus hypersecretion in the bronchial airways of ADA-deficient mice. Lung sections were stained with PAS for the detection of neutral
mucins. (a) Control lung at postpartum day 18. (b) ADA-deficient lung at postpartum day 18. (c) ADA-deficient lung at postnatal day 21. Arrows in b
and c denote PAS-positive material indicative of increased mucus production. B, bronchiole. Bars, 100 mm.163 Blackburn et al.
however, alveolar size remained enlarged in ADA-deficient
lungs at postpartum day 10 (Fig. 3 f). Quantitation of alve-
olar size (Fig. 3 g) verified that there was a significant dif-
ference in alveolar size at day 5, suggesting that alveolar
formation in ADA-deficient mice was disturbed early in
life and worsened by day 10. Lung inflammation was not
seen in ADA-deficient lungs at day 0 and day 5 as deter-
mined by H&E staining (Fig. 3) and mMBP-1 immu-
nostaining (data not shown). Slight inflammation was seen at
day 10 (Fig. 3 f), and increased numbers of alveolar mac-
rophages and eosinophils were consistently seen at day 15
(data not shown; 15). These results demonstrated that there
was a defect in alveogenesis in ADA-deficient mice and
that these defects preceded the appearance of lung inflam-
mation.
Serum IgE and BALF IL-5 Levels Are Elevated in ADA-
deficient Mice. Elevated IgE and eosinophilia are features
noted in some subsets of ADA-deficient patients (8, 38,
39). Total serum IgE levels were assessed to determine
whether elevations in IgE were associated with the lung
eosinophilia seen in ADA-deficient mice. Serum IgE levels
were slightly increased on postpartum day 18 (Fig. 4 a);
however, when the ratios of IgE to total Ig were compared
in control and ADA-deficient mice (Fig. 4 b), a prominent
bias towards IgE production was seen in ADA-deficient
animals.
Cytokine levels in BALF of 18-d-old ADA-deficient
mice were examined to investigate whether the lung in-
flammation seen was associated with a Th2 cytokine pro-
file. Though there was a trend toward a reduction in the
levels of IFN-g in ADA-deficient BALF, the differences
were not significant (Fig. 4 c). There was no difference in
the levels of IL-4 in ADA-deficient BALF; however, slight
increases in IL-5 were noted (Fig. 4 c). These findings sug-
gested that IL-5 signaling may be involved in the eosino-
philia seen in ADA-deficient mice.
ADA Enzyme Therapy Results in the Reduction of BALF
and Circulating Eosinophils and a Decrease in Mucus Production
by Bronchial Airways. PEG-ADA enzyme therapy is a
lifesaving strategy used to treat ADA-deficient patients
(40). ADA-deficient mice maintained on weekly injec-
tions of PEG-ADA from birth did not show signs of ab-
Figure 3. Defects in alveogenesis in ADA-
deficient mice. Lungs from age-matched con-
trol and ADA-deficient mice were collected
and processed for H&E staining. (a) Control
lung at postpartum day 0. (b) ADA-deficient
lung at day 0. (c) Control lung at day 5. (d)
ADA-deficient lung at day 5. (e) Control lung
at day 10 demonstrating the septation of pre-
sumptive alveoli into mature alveolar sacs. (f)
ADA-deficient lung at day 10 demonstrating
enlarged alveolar spaces. Panels a–f are at the
same magnification; bars, 250 mm. (g) The size
of alveolar airways was determined in control
(white bars, n 5 4) and ADA-deficient (black
bars, n 5 4) lungs by measuring mean chord
lengths (in mm) of alveolar airways in H&E-
stained lungs. Values are given as mean mm 6
SE from four separate age-matched control and
ADA-deficient lung pairs at each developmen-
tal stage; *P # 0.05.164 Lung Inflammation and Damage in ADA-deficient Mice
normal alveogenesis, lung eosinophilia, or respiratory dis-
tress, and survived as long as they were maintained on
PEG-ADA (data not shown). To determine if PEG-ADA
treatments could reverse the pulmonary phenotype after its
onset, ADA-deficient mice were allowed to develop se-
vere lung inflammation (day 18) and were subsequently
treated with PEG-ADA. Within 24–48 h, their respiratory
status was noticeably improved, and these animals recov-
ered and survived as long as they were maintained on
PEG-ADA (data not shown). Cell populations were mon-
itored in BALF collected 72 h after treatment with PEG-
ADA to determine what effect PEG-ADA treatment had
on lung inflammation (Fig. 5). The most striking observa-
tion was a substantial decrease in the number of eosinophils
in BALF of ADA-deficient mice treated with PEG-ADA.
The numbers of alveolar macrophages were not reduced
at 72 h after PEG-ADA treatment, but were reduced after
2 wk of enzyme therapy (Fig. 5). These findings suggested
that PEG-ADA enzyme therapy led to a rapid reduction in
lung eosinophilia in ADA-deficient mice.
ADA-deficient mice are lymphopenic, showing a two-
to threefold reduction in the number of circulating lym-
phocytes (15). Complete blood cell counts were assessed in
ADA-deficient mice and ADA-deficient mice treated with
PEG-ADA to determine if the improvement in lung in-
flammation was related to an improvement in lymphocyte
counts. There was a twofold decrease in the number of
lymphocytes seen in the periphery of ADA-deficient mice
(Table I); however, there was not a significant improve-
ment in the number of lymphocytes found in the circu-
lation after PEG-ADA treatment. There was a twofold
elevation in the number of peripheral eosinophils in ADA-
deficient mice, and peripheral eosinophil numbers were
normalized after PEG-ADA treatment. These data sug-
gested that the PEG-ADA treatments used in this study did
not have a significant impact on the lymphopenia seen in
ADA-deficient mice, but were capable of reducing eleva-
tions in lung and circulating eosinophils.
The amount of alveolar and bronchial tissue damage was
quantitated before and after PEG-ADA treatments to de-
termine what effect PEG-ADA treatments had on this
damage. The severe alveolar defect seen in ADA-deficient
mice was not significantly improved 72 h after treatment
with PEG-ADA (Fig. 6 a). In contrast, the mucus produc-
tion seen in the bronchial airways was substantially lower
72 h after PEG-ADA treatments (Fig. 6 b). Collectively,
these results suggested that restoring ADA enzymatic activ-
ity to ADA-deficient mice decreased the number of eosin-
ophils found in BALF and attenuated mucus production in
bronchial airways, but did not reverse the abnormal lung
structure resulting from abnormal alveogenesis and lung in-
flammation.
Treatment of ADA-deficient Mice with PEG-ADA Results
in Normalization of Lung Adenine Nucleoside Levels. The
elevated levels of adenosine, and to a lesser extent 29-
deoxyadenosine, in the lungs of ADA-deficient mice (15)
suggested that pulmonary inflammation observed in these
mice was due to disturbances in adenine metabolism. The
rapid reversal of respiratory distress and lung eosinophilia
Figure 4. Levels of serum IgE and BALF cytokines in control (white
bars) and ADA-deficient (black bars) mice. (a) Total IgE levels were mea-
sured in the serum of 18-d-old control (n 5 11) and ADA-deficient (n 5
8) mice. Mean total serum IgE values are given as ng/ml 6 SE. Total se-
rum Ig [IgG 1 IgM] levels are decreased 67% in ADA-deficient mice
(reference 15). (b) Ratios of IgE to Ig in control and ADA-deficient mice,
demonstrating a significant bias towards hyper IgE in ADA-deficient
mice. Statistical significance was determined using Student’s t test analysis;
*P # 0.100, **P # 0.05. (c) The levels of IFN-g, IL-4, and IL-5 were
measured in BALF collected from 18-d-old control (n 5 10) and ADA-
deficient (n 5 7) mice. Mean values are given as pg/ml 6 SE.
Figure 5. Reversible lung eosinophilia in ADA-deficient mice treated
with PEG-ADA. Total cellular differentials were determined on cells col-
lected from BALF of 18-d-old control mice (n 5 19, white bars), ADA-
deficient mice (n 5 12, black bars), and ADA-deficient mice treated with
PEG-ADA and examined 3 d later (n 5 5, hatched bars) or after 2 wk of
enzyme therapy (n 5 4, stippled bars). Mean values are given as total cells 6
SE. Statistical significance was determined using Student’s t test analysis;
*P # 0.02.165 Blackburn et al.
after PEG-ADA enzyme therapy further suggested that the
efficacy of this treatment was a consequence of lowering
adenosine and 29-deoxyadenosine levels. This was con-
firmed by examining the levels of ADA substrates in ADA-
deficient lungs after PEG-ADA treatments (Fig. 7). The
levels of adenosine in control lungs at day 18 were ,0.2
nmol/mg protein, whereas adenosine levels in the lungs of
ADA-deficient mice were elevated .20-fold (6.3 nmol/
mg protein). 29-Deoxyadenosine was not detected in con-
trol lungs and was elevated to 0.05 nmol/mg protein in
ADA-deficient lungs. Strikingly, 72 h after treatment with
PEG-ADA, adenosine and 29-deoxyadenosine levels were
lowered to near control levels in ADA-deficient lungs.
These studies demonstrated that PEG-ADA enzyme ther-
apy could efficiently remove adenosine and 29-deoxyaden-
osine from the lungs of ADA-deficient mice, and sug-
gested that accumulations of these nucleosides may play a
role in regulating the lung eosinophilia and mucus produc-
tion seen.
Genetic Replacement of ADA Prevents Lung Metabolic Dis-
turbances and the Development of Histopathologies. The re-
sults obtained using PEG-ADA provided compelling evi-
dence that adenine metabolic disturbances were associated
with the onset and progression of the pulmonary changes
occurring in ADA-deficient mice. Therefore, we hypothe-
sized that genetically providing an enriched source of ADA
to these mice would prevent metabolic disturbances and
pulmonary changes. To this end, we examined the status of
lung structure, inflammation, and metabolic disturbances in
ADA-deficient mice in which expression of ADA was spe-
cifically targeted to the forestomach (19). The forestomach
was chosen because it is an enriched site of ADA production,
and gene regulatory elements necessary for forestomach-
specific expression were available (41). Transgenic expres-
sion of ADA in the forestomach of otherwise ADA-defi-
cient mice (Fig. 8 e) prevented respiratory distress, allowing
the animals to live a normal life span. Examination of lung
histology revealed that these mice were comparable to con-
trol animals, and did not exhibit signs of abnormal alveo-
genesis, or increases in alveolar macrophages or eosinophils
(Fig. 8, a–c; BALF data not shown). Correspondingly, aden-
osine and 29-deoxyadenosine levels in the lungs of these
animals were not significantly elevated (Fig. 8 d). Collec-
tively, these data suggested that enriched expression of ADA
in the forestomach of ADA-deficient mice could prevent
the accumulation of adenosine and 29-deoxyadenosine in
the lung as well as pulmonary histopathologies and inflam-
mation associated with these accumulations.
Discussion
Results presented in this study demonstrate that the met-
abolic disturbances associated with ADA deficiency in mice
Figure 6. Quantification of lung histopathology in ADA-deficient
mice and ADA-deficient mice treated with PEG-ADA. (a) Mean cord
lengths of alveolar airways were determined in lungs of 18-d-old control
and ADA-deficient mice, and lungs of 21-d-old mice 72 h after treatment
with PEG-ADA. Values are given as mean cord lengths in mm 6 SE, n 5
5 for each condition. *P # 0.02 for increases in mean cord lengths com-
pared with controls. (b) The degree of mucus production was determined
in the bronchial airways of 18-d-old control and ADA-deficient mice,
and 21-d-old ADA-deficient mice 3 d after treatment with PEG-ADA.
Values are given as mean airway mucus indices in arbitrary pixel units 6
SE, n 5 5 for each condition. Statistical significance was determined using
Student’s t test analysis; *P # 0.01 for an increase in mucus index be-
tween control and ADA-deficient samples, **P # 0.02 for a decrease in
mucus index between ADA-deficient samples and PEG-ADA–treated
ADA-deficient samples.
Figure 7. PEG-ADA treatments reverse accumulations of adenosine
and 29-deoxyadenosine in the lungs of ADA-deficient mice. Adenosine
and 29-deoxyadenosine levels were quantitated in the lungs of 18-d-old
control mice (n 5 5) and ADA-deficient mice (n 5 4), and 21-d-old
ADA-deficient mice 3 d after treatment with PEG-ADA (n 5 4). Mean
values are given as nmol/mg protein 6 SE. Statistical significance was de-
termined using Student’s t test analysis; *P # 0.002. nd, not detectable at
a minimal detection limit of 0.001 nmol/mg protein.166 Lung Inflammation and Damage in ADA-deficient Mice
result in abnormal lung development and the promotion of
lung inflammation and damage. ADA-deficient mice ex-
hibited alveolar defects that were overcome by genetically
restoring ADA enzymatic activity to these animals. In addi-
tion, lowering ADA substrates in the lung using enzyme
therapy reversed lung eosinophilia and mucus production.
The ADA substrates adenosine and 29-deoxyadenosine
both have potent cellular signaling properties, some of
which have been implicated to play a role in lung inflam-
mation. These mice will therefore serve as a useful in vivo
model system in which to study the role of purinergic sig-
naling in aspects of lung development and disease.
Defects in alveogenesis have been noted in mice defi-
cient in various growth factor signaling pathways, including
fibroblast growth factor (42), platelet-derived growth factor
(43), and transforming growth factor b (44) signaling path-
ways. In addition, overexpression of cytokines such as IL-
11 (45) and IL-13 (46) in the lungs of mice results in de-
fects in alveogenesis. These findings suggest that this stage
of lung development is influenced by complex signaling
pathways. Developmental analysis of lung structure in
ADA-deficient mice revealed a defect in alveolarization.
This defect preceded the onset of lung inflammation. The
pronounced elevations of adenosine in ADA-deficient
lungs suggested that perturbations in adenosine signaling
may play a role in the alveolar defect seen. Nothing is
known with regard to the expression of adenosine recep-
tors during lung development, and examining the expres-
sion of adenosine receptors in normal and ADA-deficient
lungs will help clarify the role of adenosine signaling during
normal and abnormal alveogenesis.
ADA-deficient mice develop and succumb to severe
pulmonary inflammation and lung damage by 3 wk of age
(15). Characterization of the inflammation revealed a large
accumulation of activated macrophages throughout the
lungs and an infiltration of eosinophils around pulmonary
blood vessels and bronchial airways. The inflammation was
progressive, with no inflammation evident until postpar-
tum day 10, after which lung inflammation increased in
severity. This inflammation was associated with a pro-
nounced increase in mucus production and a marked
increase in lung adenosine levels. The observation that
lowering adenosine levels improved pulmonary inflamma-
tion and mucus production suggested that adenosine may
mediate these processes. Consistent with this suggestion is
the extensive literature base showing that adenosine plays a
role in inflammatory lung diseases such as asthma and
chronic obstructive pulmonary disease (for a review, see
reference 20). The exact functions that this signaling nucle-
oside plays in lung disease are not known, but they likely
depend on the type of inflammatory cells present and the
distribution of adenosine receptors on these cells. The abil-
Figure 8. Transgenic expression of ADA
in the forestomach of ADA-deficient mice
prevents adenosine and 29-deoxyadenosine
accumulation, lung inflammation, and lung
histopathologies. (a) H&E-stained section of
an 18-d-old control lung. (b) H&E-stained
section of a 21-d-old ADA-deficient lung.
(c) H&E-stained section of a 21-d-old
ADA-deficient lung of a mouse expressing
an ADA minigene in its forestomach. Bars,
(a–c) 250 mm. (d) Adenosine and 29-deoxy-
adenosine levels were quantitated in the
lungs of 21-d-old control, ADA-deficient,
or ADA-deficient mice expressing ADA in
their forestomach (forestomach rescue).
Mean values are given as nmol/mg protein
6 SE; n 5 3 for each. Statistical significance
was determined using Student’s t test analy-
sis; *P # 0.002. nd, not detected at a mini-
mal detection limit of 0.001 nmol/mg pro-
tein. (e) Zymogram analysis showing the
level of ADA enzymatic activity in the lung
(L), blood (Bl), and forestomach (FS) of 21-
d-old control, ADA-deficient, and ADA-
deficient mice expressing ADA in their
forestomach. Purine nucleoside phosphory-
lase (PNP) was used as a positive control.167 Blackburn et al.
ity to control adenosine levels in ADA-deficient mice using
enzyme replacement therapy will provide a useful model
for examining the influence of adenosine on different in-
flammatory cells in vivo.
Eosinophils have emerged as a major inflammatory cell
type in asthma, and an increase in eosinophils is often ob-
served in the lungs of asthmatics (47). These cells can re-
lease mediators that contribute to the airway damage often
associated with asthma such as bronchial epithelial cell
damage and the stimulation of mucus production (48, 49).
The accumulation of eosinophils in the lungs of ADA-defi-
cient mice may be responsible for the increased mucus pro-
duction seen. This is supported by the observation that
decreasing the number of eosinophils in the lungs of ADA-
deficient mice using ADA enzyme therapy also resulted in
decreased mucus production. Alternatively, the decreased
mucus production may be a direct effect of lowering lung
adenosine levels since adenosine signaling has been demon-
strated to increase mucus secretion in a canine mucus
model (50). Increased mucus production in ADA-deficient
mice was not associated with an increase in IL-4 in the
BALF, suggesting the production of mucus in this model
was not IL-4 dependent. Whether the mucus production
was mediated by other Th2 cytokines such as IL-13 or
IL-9, or by eosinophil-derived mediators or adenosine itself,
remains to be determined.
The involvement of adenosine signaling in eosinophil
biology has been demonstrated. The A3 adenosine receptor
is expressed on human eosinophils that accumulate in the
lung (23), and engagement of this receptor on eosinophils
is thought to mediate the release of Ca21 from intracellular
stores (29), inhibit superoxide release (28), and inhibit eosin-
ophil chemotaxis, which may serve a pro- or antiinflamma-
tory role (23, 27). Whether or not the A3 receptor is
expressed in murine eosinophils and in the lungs of ADA-
deficient mice is currently under investigation. However,
the large increase in lung eosinophils in ADA-deficient
mice and the ability to rapidly reverse this eosinophilia by
lowering adenosine concentrations suggest that adenosine
signaling may be mediating the lung eosinophilia occurring
in these mice.
In addition to an increase in eosinophils, the number and
activation of alveolar macrophages were greatly increased
in the lungs of ADA-deficient mice. Engagement of aden-
osine receptors on macrophages elicits both pro- and anti-
inflammatory events, including the inhibition of TNF-a
expression (51, 52) and nitric oxide production (51), in-
creased production of IL-10 (51), increased differentiation
of monocytes into macrophages (31, 32, 53), increased
rates of phagocytosis (32), and stimulation of giant cell for-
mation (30). Therefore, the increased number and activity
of alveolar macrophages and giant cells in ADA-deficient
mice may result from aberrant adenosine signaling brought
about by persistent elevations in lung adenosine levels. Ac-
tivated macrophages can contribute to alveolar airway
damage (54). The enlargement of the alveolar airways in
ADA-deficient mice is associated with a defect in alveo-
genesis. However, the enlargement of these airways is pro-
gressive from postpartum day 15 to 18, suggesting that
damage to these airways is also occurring. The large num-
ber of activated macrophages found in the alveolar airways
of these mice may contribute to the increased damage seen.
The determination of proteolytic enzyme production by
these macrophages and the influence of adenosine signaling
on this process will help clarify the role of activated mac-
rophages in this model. The number of macrophages found
in the lungs of ADA-deficient mice was not altered 72 h af-
ter PEG-ADA treatments, nor was there any improvement
in the alveolar damage seen. The persistence of macrophages
may indicate that these cells are actively involved in the
clearance of cellular debris resultant of the severe eosino-
philia and tissue damage seen. The ability to control aden-
osine levels using varying doses of PEG-ADA will provide
a useful tool to explore the involvement of adenosine sig-
naling in both eosinophil and macrophage function.
ADA deficiency in humans is most commonly associated
with a combined immunodeficiency (7). However, addi-
tional phenotypes have been described, including bone and
renal abnormalities (12), hepatocellular damage (13), neu-
rological disorders, and pulmonary insufficiencies (7).
Although the treatment of ADA-deficient patients with PEG-
ADA has rapid beneficial effects on some of these pheno-
types (14, 55), it is still not clear whether they are a primary
consequence of the ADA deficiency. Here, we demonstrate
that ADA enzyme therapy can rapidly reverse respiratory
distress in ADA-deficient mice in conjunction with lower-
ing lung adenosine and 29-deoxyadenosine levels, suggest-
ing that the respiratory distress seen in this model is a direct
consequence of ADA deficiency. This suggestion is sup-
ported by observations that the ADA enzyme therapy pro-
tocol used did not improve the immune status in these
animals. Pulmonary insufficiency is common in ADA-defi-
cient patients, and these insufficiencies are most often at-
tributed to bacterial or viral pneumonia that arises from a
compromised immune system. However, in many cases of
interstitial pneumonia an organism cannot be isolated (7).
Our observations in ADA-deficient mice suggest that it is
possible that the adenine metabolic disturbances in ADA-
deficient patients may directly contribute to the pulmonary
insufficiency occurring in this population.
Some ADA-deficient patients have been shown to have
elevated levels of IgE, eosinophilia, and an increased inci-
dence of asthma (8, 38, 39). These individuals are typically
patients with delayed or late onset ADA deficiency and
thus have milder forms of immunodeficiency (7, 8). ADA-
deficient mice exhibited an increase in serum IgE, eosino-
philia, and developed lung inflammatory changes, suggest-
ing that they resemble patients with a less severe form of
ADA deficiency. Consistent with this is the observation
that the immunodeficiency seen in ADA-deficient mice is
not as severe as that seen in completely ADA-deficient hu-
mans (15). However, the immunodeficiency seen in these
animals must be considered when trying to understand the
nature of the lung inflammation seen. Lung eosinophilia is
often associated with a Th2 cytokine profile (56). How-
ever, there was not a robust Th2 cytokine profile in BALF168 Lung Inflammation and Damage in ADA-deficient Mice
collected from ADA-deficient mice. Since Th2 cytokines
such as IL-4 are produced largely by CD4 T cells, the im-
munodeficiency seen in ADA-deficient mice may impact
the relative capability to generate Th2 cytokines. Alterna-
tively, the absence of a robust Th2 response suggests that
other signaling pathways are involved in mediating the
lung eosinophilia seen.
In conclusion, by deleting the enzyme responsible for
controlling the levels of adenosine and 29-deoxyadenosine,
we have generated animals that exhibit adenine metabolic
disturbances in association with alveolar defects and the de-
velopment of severe pulmonary inflammation. Lung eosin-
ophilia was reduced and the animals were rescued from
respiratory distress by lowering adenosine and 29-deoxyad-
enosine levels using ADA enzyme therapy. Although 29-
deoxyadenosine–mediated effects on this phenotype cannot
be ruled out, there is substantial evidence to suggest aden-
osine signaling may be playing an important role in the
type of inflammation and tissue damage seen (20). Defining
the adenosine receptors expressed on eosinophils, mac-
rophages, and in the lungs of ADA-deficient mice, and us-
ing pharmacological and genetic technologies to assess their
function, will help us to understand how adenosine influ-
ences lung inflammation in this model. This may in turn
help guide new therapies for the treatment of lung condi-
tions in which eosinophils and macrophages are thought to
mediate damage, including asthma, idiopathic eosinophilic
lung inflammation, chronic obstructive pulmonary disease,
and emphysema. The correlation of increased lung adeno-
sine and asthma (21) and the ability to relieve lung eosino-
philia in mice by lowering adenosine levels raise the possi-
bility that ADA enzyme therapy may be beneficial in the
treatment of eosinophilic lung inflammation. Using ADA-
deficient mice as a testing ground to understand the basis
for adenosine-dependent lung eosinophilia will aid in eval-
uating the efficacy of such therapies.
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